期刊
EMBO REPORTS
卷 20, 期 4, 页码 -出版社
WILEY
DOI: 10.15252/embr.201846685
关键词
cancer; cholesterol; endolysosomes; HRAS; TRPML1
资金
- Cancer Prevention and Research Institute of Texas (CPRIT) grant [170691]
- NCI [P30CA125123]
- P30 Cancer Center Support Grant [NCI-CA125123]
- CPRIT [RP170233]
- NIH [R00CA188593, R01NS08130, R21NS094860]
- PENN Orphan Disease Center [MDBR-18-132-RAS]
By serving as intermediaries between cellular metabolism and the bioenergetic demands of proliferation, endolysosomes allow cancer cells to thrive under normally detrimental conditions. Here, we show that an endolysosomal TRP channel, TRPML1, is necessary for the proliferation of cancer cells that bear activating mutations in HRAS. Expression of MCOLN1, which encodes TRPML1, is significantly elevated in HRAS-positive tumors and inversely correlated with patient prognosis. Concordantly, MCOLN1 knockdown or TRPML1 inhibition selectively reduces the proliferation of cancer cells that express oncogenic, but not wild-type, HRAS. Mechanistically, TRPML1 maintains oncogenic HRAS in signaling-competent nanoclusters at the plasma membrane by mediating cholesterol de-esterification and transport. TRPML1 inhibition disrupts the distribution and levels of cholesterol and thereby attenuates HRAS nanoclustering and plasma membrane abundance, ERK phosphorylation, and cell proliferation. These findings reveal a selective vulnerability of HRAS-driven cancers to TRPML1 inhibition, which may be leveraged as an actionable therapeutic strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据